



# CD45 Monoclonal Antibody (HI30), APC, eBioscience™

<b>Product Details</b>	
Size	100 Tests
Species Reactivity	Human
Published Species	Human, Mouse
Host/Isotype	Mouse / IgG1, kappa
Recommended Isotype Control	Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), APC, eBioscience™
Class	Monoclonal
Туре	Antibody
Clone	HI30
Conjugate	APC
Excitation/Emission Max	651/660 nm
Form	Liquid
Concentration	5 μL/Test
Purification	Affinity chromatography
Storage buffer	PBS, pH 7.2, with 0.2% BSA
Contains	0.09% sodium azide
Storage conditions	4° C, store in dark, DO NOT FREEZE!
RRID	AB_10667894

Applications	Tested Dilution	Publications
Immunocytochemistry (ICC/IF)	-	1 Publication
Flow Cytometry (Flow)	5 μL (0.06 μg)/test	55 Publications

#### **Product Specific Information**

Description: The HI30 monoclonal antibody reacts with all isoforms of human CD45, also known as Leukocyte Common Antigen (LCA). CD45 is expressed by all hematopoietic cells excluding circulating erythrocytes and platelets. The cytoplasmic portion of CD45 has tyrosine phosphatase enzymatic activity and plays an important role in activation of lymphocytes.


Applications Reported: The HI30 antibody has been reported for use in flow cytometric analysis.

Applications Tested: This HI30 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5  $\mu$ L (0.06  $\mu$ g) per test. A test is defined as the amount ( $\mu$ g) of antibody that will stain a cell sample in a final volume of 100  $\mu$ L. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser.


Filtration: 0.2 µm post-manufacturing filtered.

# Product Images For CD45 Monoclonal Antibody (HI30), APC, eBioscience™



#### CD45 Antibody (17-0459-42) in Flow

Staining of normal human peripheral blood cells with Mouse IgG1 K Isotype Control APC (Product # 17-4714-81) (blue histogram) or Anti-Human CD45 APC (purple histogram). Cells in the lymphocyte gate were used for analysis.



## CD45 Antibody (17-0459-42)

Antibody clone (HI30) specificity was demonstrated by CRISPR-Cas9 mediated knockout of target protein. Lossof signal was observed for target protein in HI30 KOcells (blue histogram) compared to the control Cas9cells (pink histogram) using CD45 antibody (HI30). The Yellow histogram represents staining with the isotype control. {KO}

View more figures on thermofisher.com

#### **□ 56 References**

#### Immunocytochemistry (1)

Translational lung cancer research

Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients.

"17-0459-42 was used in Immunocytochemistry to evaluate a protocol using two VyCAP microsieves to filter DLA product of NSCLC patients and enumerate CTC, compared with CellSearch as a gold standard."

Authors: Tamminga M,Oomens L,Hiltermann TJN,Andree KC,Tibbe A,Broekmaat J,Schuuring E,Terstappen LWMM, Groen H IM

**Year** 2020

Species Human

## Flow Cytometry (55)

International journal of molecular sciences

STS1 and STS2 Phosphatase Inhibitor Baicalein Enhances the Expansion of Hematopoietic and Progenitor Stem Cells and Alleviates 5-Fluorouracil-Induced Myelosuppression.

"17-0459-42 was used in Flow cytometry/Cell sorting to suggest BC as one of the small molecule candidates to stimulate HSPC expansion both in vitro and in vivo when needed in either physiologic or pathologic conditions, but also supports STS1/STS2 as potential therapeutic drug targets for HSPC expansion and hematopoietic injury recovery."

Authors: Li N, Wang Y, Wang A, Zhang J, Jia C, Yu C, Song Z, Wang S, Liu L, Yi J, Bao Y, Huang Y, Sun L

**Year** 2023

Species Human Mouse

Folia histochemica et cytobiologica

Astragaloside IV - mediated endothelial progenitor cell exosomes promote autophagy and inhibit apoptosis in hyperglycemic damaged endothelial cells via miR-21/PTEN axis.

"17-0459-42 was used in Flow cytometry/Cell sorting to demonstrate that AS-IV-mediated EPC-exos-miR-21 enhances autophagy and depresses apoptosis in HG-damaged endothelial cells via the miR-21/PTEN axis."

Authors: Xiong W,Huang XL,Li CY,Wang XL,Lan HW,Wang TT,Chen ZL,Yang QP,Hu AL,Xia YF,Zhu FR,Zhou ZZ

**Year** 2023

Species Human

View more Flow references on thermofisher com

## More applications with references on thermofisher.com

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"), No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is made and represent the product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample incribed to Buyer is merely illustrative of the general type and quality of goods not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE. OR NON INFRINGEMENT.

BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACE OR REFUND FOR PRODUCTS, AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AT THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH TH